Literature DB >> 16988804

[Cardioprotection by means of Candesartan in cardiac insufficiency. CHARM overall partial evaluation (Candesartan in heart failure assessment of reduction in mortality and morbidity)].

C Tschöpe1, H P Schultheiss.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16988804     DOI： 10.1007/s00108-006-1710-z

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN： 0020-9554            Impact factor:   0.743


× No keyword cloud information.
  7 in total

1.  Angiotensin receptor blockers and myocardial infarction.

Authors:  Subodh Verma; Marty Strauss
Journal:  BMJ       Date:  2004-11-27

2.  2004 ACC/AHA guideline for the management of patients with STEMI: the implications for clinicians.

Authors:  Robert P Giugliano; Eugene Braunwald
Journal:  Nat Clin Pract Cardiovasc Med       Date:  2005-03

Review 3.  ACE inhibitors in heart failure: what more do we need to know?

Authors:  Catherine Demers; Anita Mody; Koon K Teo; Robert S McKelvie
Journal:  Am J Cardiovasc Drugs       Date:  2005       Impact factor: 3.571

4.  Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure.

Authors:  Catherine Demers; John J V McMurray; Karl Swedberg; Marc A Pfeffer; Christopher B Granger; Bertil Olofsson; Robert S McKelvie; Jan Ostergren; Eric L Michelson; Peter A Johansson; Duolao Wang; Salim Yusuf
Journal:  JAMA       Date:  2005-10-12       Impact factor: 56.272

Review 5.  Angiotensin receptor blockers versus ACE inhibitors: prevention of death and myocardial infarction in high-risk populations.

Authors:  Benjamin J Epstein; John G Gums
Journal:  Ann Pharmacother       Date:  2005-02-08       Impact factor: 3.154

6.  Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions.

Authors:  S Yusuf; C J Pepine; C Garces; H Pouleur; D Salem; J Kostis; C Benedict; M Rousseau; M Bourassa; B Pitt
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

7.  The effect of valsartan, captopril, or both on atherosclerotic events after acute myocardial infarction: an analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT).

Authors:  John McMurray; Scott Solomon; Karen Pieper; Shelby Reed; Jean Rouleau; Eric Velazquez; Harvey White; Jonathan Howlett; Karl Swedberg; Aldo Maggioni; Lars Køber; Frans Van de Werf; Rob Califf; Marc Pfeffer
Journal:  J Am Coll Cardiol       Date:  2006-01-26       Impact factor: 24.094
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.